These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25348954)

  • 1. Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.
    Bai Y; Kim JY; Watters JM; Fang B; Kinose F; Song L; Koomen JM; Teer JK; Fisher K; Chen YA; Rix U; Haura EB
    Cancer Res; 2014 Dec; 74(24):7217-7228. PubMed ID: 25348954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
    Hammerman PS; Sos ML; Ramos AH; Xu C; Dutt A; Zhou W; Brace LE; Woods BA; Lin W; Zhang J; Deng X; Lim SM; Heynck S; Peifer M; Simard JR; Lawrence MS; Onofrio RC; Salvesen HB; Seidel D; Zander T; Heuckmann JM; Soltermann A; Moch H; Koker M; Leenders F; Gabler F; Querings S; Ansén S; Brambilla E; Brambilla C; Lorimier P; Brustugun OT; Helland A; Petersen I; Clement JH; Groen H; Timens W; Sietsma H; Stoelben E; Wolf J; Beer DG; Tsao MS; Hanna M; Hatton C; Eck MJ; Janne PA; Johnson BE; Winckler W; Greulich H; Bass AJ; Cho J; Rauh D; Gray NS; Wong KK; Haura EB; Thomas RK; Meyerson M
    Cancer Discov; 2011 Jun; 1(1):78-89. PubMed ID: 22328973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.
    Beauchamp EM; Woods BA; Dulak AM; Tan L; Xu C; Gray NS; Bass AJ; Wong KK; Meyerson M; Hammerman PS
    Mol Cancer Ther; 2014 Feb; 13(2):475-82. PubMed ID: 24296828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants.
    Iwai LK; Payne LS; Luczynski MT; Chang F; Xu H; Clinton RW; Paul A; Esposito EA; Gridley S; Leitinger B; Naegle KM; Huang PH
    Biochem J; 2013 Sep; 454(3):501-13. PubMed ID: 23822953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.
    Xu C; Buczkowski KA; Zhang Y; Asahina H; Beauchamp EM; Terai H; Li YY; Meyerson M; Wong KK; Hammerman PS
    Mol Cancer Ther; 2015 Oct; 14(10):2382-2389. PubMed ID: 26206333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.
    Pitini V; Arrigo C; Di Mirto C; Mondello P; Altavilla G
    Lung Cancer; 2013 Oct; 82(1):171-2. PubMed ID: 23932362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients.
    Miao L; Wang Y; Zhu S; Shi M; Li Y; Ding J; Yang J; Ye Q; Cai H; Zhang D; Liu H; Song Y
    BMC Cancer; 2014 May; 14():369. PubMed ID: 24885564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discoidin domain receptor 2 signaling networks and therapy in lung cancer.
    Payne LS; Huang PH
    J Thorac Oncol; 2014 Jun; 9(6):900-4. PubMed ID: 24828669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.
    Day E; Waters B; Spiegel K; Alnadaf T; Manley PW; Buchdunger E; Walker C; Jarai G
    Eur J Pharmacol; 2008 Dec; 599(1-3):44-53. PubMed ID: 18938156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine 740 phosphorylation of discoidin domain receptor 2 by Src stimulates intramolecular autophosphorylation and Shc signaling complex formation.
    Yang K; Kim JH; Kim HJ; Park IS; Kim IY; Yang BS
    J Biol Chem; 2005 Nov; 280(47):39058-66. PubMed ID: 16186108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.
    Terai H; Tan L; Beauchamp EM; Hatcher JM; Liu Q; Meyerson M; Gray NS; Hammerman PS
    ACS Chem Biol; 2015 Dec; 10(12):2687-96. PubMed ID: 26390252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer.
    Nicoś M; Powrózek T; Krawczyk P; Jarosz B; Pająk B; Sawicki M; Kucharczyk K; Trojanowski T; Milanowski J
    Med Oncol; 2014 Oct; 31(10):176. PubMed ID: 25173530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An essential role of discoidin domain receptor 2 (DDR2) in osteoblast differentiation and chondrocyte maturation via modulation of Runx2 activation.
    Zhang Y; Su J; Yu J; Bu X; Ren T; Liu X; Yao L
    J Bone Miner Res; 2011 Mar; 26(3):604-17. PubMed ID: 20734453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
    Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB
    Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
    Lin YC; Wu MH; Wei TT; Chuang SH; Chen KF; Cheng AL; Chen CC
    Neoplasia; 2012 Jun; 14(6):463-75. PubMed ID: 22787428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.
    Terashima M; Togashi Y; Sato K; Mizuuchi H; Sakai K; Suda K; Nakamura Y; Banno E; Hayashi H; De Velasco MA; Fujita Y; Tomida S; Mitsudomi T; Nishio K
    Clin Cancer Res; 2016 Jul; 22(14):3663-71. PubMed ID: 26826182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
    Okamoto W; Okamoto I; Yoshida T; Okamoto K; Takezawa K; Hatashita E; Yamada Y; Kuwata K; Arao T; Yanagihara K; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 May; 9(5):1188-97. PubMed ID: 20406949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.
    Lee MS; Jung EA; An SB; Kim YJ; Oh DY; Song JY; Um SW; Han J; Choi YL
    Cancer Res Treat; 2017 Oct; 49(4):1065-1076. PubMed ID: 28161936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new target for therapy in squamous cell carcinoma of the lung.
    Ohashi K; Pao W
    Cancer Discov; 2011 Jun; 1(1):23-4. PubMed ID: 22586316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.